

Taku Okazaki

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9474590/taku-okazaki-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

69
papers

18,302
citations

42
h-index

70
g-index

70
ext. papers

20,915
ext. citations

11.1
avg, IF

6.19
L-index

#	Paper	IF	Citations
69	Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. <i>Journal of Experimental Medicine</i> , 2000 , 192, 1027-34	16.6	3501
68	Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 12293-7	11.5	2044
67	PD-L2 is a second ligand for PD-1 and inhibits T cell activation. <i>Nature Immunology</i> , 2001 , 2, 261-8	19.1	2040
66	Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. <i>Science</i> , 2001 , 291, 319-22	33.3	1330
65	Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 3360-5	11.5	1081
64	PD-1 and PD-1 ligands: from discovery to clinical application. <i>International Immunology</i> , 2007 , 19, 813-24	4.9	836
63	A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. <i>Nature Immunology</i> , 2013 , 14, 1212-8	19.1	611
62	PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 13866-71	11.5	600
61	The PD-1-PD-L pathway in immunological tolerance. <i>Trends in Immunology</i> , 2006 , 27, 195-201	14.4	526
60	Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. <i>Cancer</i> , 2010 , 116, 1757-66	6.4	511
59	Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. <i>Nature Medicine</i> , 2003 , 9, 1477-83	50.5	495
58	Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. <i>Nature Immunology</i> , 2005 , 6, 280-6	19.1	420
57	PD-1 inhibits antiviral immunity at the effector phase in the liver. <i>Journal of Experimental Medicine</i> , 2003 , 198, 39-50	16.6	307
56	Establishment of NOD-Pdcd1 ^{-/-} mice as an efficient animal model of type I diabetes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 11823-8	11.5	306
55	The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 3011-6	11.5	264
54	IFN- γ directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. <i>Journal of Immunology</i> , 2011 , 186, 2772-9	5.3	227
53	Molecular cloning of rat leptin receptor isoform complementary DNAs--identification of a missense mutation in Zucker fatty (fa/fa) rats. <i>Biochemical and Biophysical Research Communications</i> , 1996 , 225, 75-83	3.4	222

52	Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. <i>Immunology Letters</i> , 2002 , 84, 57-62	4.1	216
51	Role of PD-1 in regulating T-cell immunity. <i>Current Topics in Microbiology and Immunology</i> , 2011 , 350, 17-37	3.3	198
50	PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. <i>Journal of Experimental Medicine</i> , 2011 , 208, 395-407	16.6	191
49	New regulatory co-receptors: inducible co-stimulator and PD-1. <i>Current Opinion in Immunology</i> , 2002 , 14, 779-82	7.8	189
48	Molecular cloning of rat obese cDNA and augmented gene expression in genetically obese Zucker fatty (fa/fa) rats. <i>Journal of Clinical Investigation</i> , 1995 , 96, 1647-52	15.9	160
47	PD-1 deficiency results in the development of fatal myocarditis in MRL mice. <i>International Immunology</i> , 2010 , 22, 443-52	4.9	155
46	Restriction of PD-1 function by -PD-L1/CD80 interactions is required for optimal T cell responses. <i>Science</i> , 2019 , 364, 558-566	33.3	146
45	Pathophysiological significance of the obese gene product, leptin, in ventromedial hypothalamus (VMH)-lesioned rats: evidence for loss of its satiety effect in VMH-lesioned rats. <i>Endocrinology</i> , 1997 , 138, 947-54	4.8	116
44	PD-1-mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo. <i>Journal of Immunology</i> , 2009 , 182, 6682-9	5.3	115
43	Structural organization and chromosomal assignment of the human obese gene. <i>Journal of Biological Chemistry</i> , 1995 , 270, 27728-33	5.4	111
42	RBP-L, a transcription factor related to RBP-Jkappa. <i>Molecular and Cellular Biology</i> , 1997 , 17, 2679-87	4.8	109
41	Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling. <i>Gastroenterology</i> , 2008 , 135, 1333-43	13.3	87
40	LAG-3 inhibits the activation of CD4 T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII. <i>Nature Immunology</i> , 2018 , 19, 1415-1426	19.1	84
39	Intestinal CX3C chemokine receptor 1(high) (CX3CR1(high)) myeloid cells prevent T-cell-dependent colitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 5010-5 ^{11.5}	11.5	81
38	DCIR acts as an inhibitory receptor depending on its immunoreceptor tyrosine-based inhibitory motif. <i>Journal of Investigative Dermatology</i> , 2002 , 118, 261-6	4.3	70
37	PD-1/PD-L pathway and autoimmunity. <i>Autoimmunity</i> , 2005 , 38, 353-7	3	70
36	LAG-3: from molecular functions to clinical applications 2020 , 8,		70
35	Anti-programmed cell death 1 antibody reduces CD4+PD-1+ T cells and relieves the lupus-like nephritis of NZB/W F1 mice. <i>Journal of Immunology</i> , 2010 , 184, 2337-47	5.3	65

34	Microanatomical localization of PD-1 in human tonsils. <i>Immunology Letters</i> , 2002 , 83, 215-20	4.1	65
33	T-cell suppression by programmed cell death 1 ligand 1 on retinal pigment epithelium during inflammatory conditions 2009 , 50, 2862-70		63
32	Natural killer activating receptors trigger interferon gamma secretion from T cells and natural killer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 3798-803 ^{11.5}		59
31	PD-1 Primarily Targets TCR Signal in the Inhibition of Functional T Cell Activation. <i>Frontiers in Immunology</i> , 2019 , 10, 630	8.4	57
30	Dysregulated generation of follicular helper T cells in the spleen triggers fatal autoimmune hepatitis in mice. <i>Gastroenterology</i> , 2011 , 140, 1322-1333.e1-5	13.3	52
29	Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjögren's syndrome. <i>Journal of Rheumatology</i> , 2005 , 32, 2156-63	4.1	51
28	Hydronephrosis associated with antiurothelial and antinuclear autoantibodies in BALB/c-Fcgr2b-/-Pdc1-/- mice. <i>Journal of Experimental Medicine</i> , 2005 , 202, 1643-8	16.6	44
27	PD-1 deficiency reveals various tissue-specific autoimmunity by H-2b and dose-dependent requirement of H-2g7 for diabetes in NOD mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 3533-8	11.5	41
26	PD-1-PD-L1 pathway impairs T(h)1 immune response in the late stage of infection with <i>Mycobacterium bovis</i> bacillus Calmette-Guérin. <i>International Immunology</i> , 2010 , 22, 915-25	4.9	35
25	TNF- α s essential in the induction of fatal autoimmune hepatitis in mice through upregulation of hepatic CCL20 expression. <i>Clinical Immunology</i> , 2013 , 146, 15-25	9	34
24	Genomic organization, expression, and chromosomal mapping of the mouse adrenomedullin gene. <i>Genomics</i> , 1996 , 37, 395-9	4.3	34
23	Pathogenic roles of cardiac autoantibodies in dilated cardiomyopathy. <i>Trends in Molecular Medicine</i> , 2005 , 11, 322-6	11.5	32
22	Rejuvenating exhausted T cells during chronic viral infection. <i>Cell</i> , 2006 , 124, 459-61	56.2	28
21	Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation. <i>Journal of Biological Chemistry</i> , 2019 , 294, 6017-6026	5.4	23
20	Paradoxical development of polymyositis-like autoimmunity through augmented expression of autoimmune regulator (AIRE). <i>Journal of Autoimmunity</i> , 2018 , 86, 75-92	15.5	16
19	Glucocorticoids potentiate the inhibitory capacity of programmed cell death 1 by up-regulating its expression on T cells. <i>Journal of Biological Chemistry</i> , 2019 , 294, 19896-19906	5.4	16
18	PD-1 Imposes Qualitative Control of Cellular Transcriptomes in Response to T Cell Activation. <i>Molecular Cell</i> , 2020 , 77, 937-950.e6	17.6	15
17	The programmed death-1 and interleukin-10 pathways play a down-modulatory role in LP-BM5 retrovirus-induced murine immunodeficiency syndrome. <i>Journal of Virology</i> , 2008 , 82, 2456-69	6.6	13

16	PD-1 aborts the activation trajectory of autoreactive CD8 T cells to prohibit their acquisition of effector functions. <i>Journal of Autoimmunity</i> , 2019 , 105, 102296	15.5	10
15	IFN- β s reciprocally involved in the concurrent development of organ-specific autoimmunity in the liver and stomach. <i>Autoimmunity</i> , 2012 , 45, 186-98	3	10
14	BALB/c-Fcgr2bPdcd1 mouse expressing anti-urothelial antibody is a novel model of autoimmune cystitis. <i>Scientific Reports</i> , 2012 , 2, 317	4.9	10
13	Identification of QTLs that modify peripheral neuropathy in NOD.H2b-Pdcd1 ^{-/-} mice. <i>International Immunology</i> , 2009 , 21, 499-509	4.9	8
12	Specific and high-affinity binding of tetramerized PD-L1 extracellular domain to PD-1-expressing cells: possible application to enhance T cell function. <i>International Immunology</i> , 2007 , 19, 881-90	4.9	7
11	Stimulatory and Inhibitory Co-signals in Autoimmunity. <i>Advances in Experimental Medicine and Biology</i> , 2019 , 1189, 213-232	3.6	7
10	PD-1 efficiently inhibits T cell activation even in the presence of co-stimulation through CD27 and GITR. <i>Biochemical and Biophysical Research Communications</i> , 2019 , 511, 491-497	3.4	5
9	Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity.. <i>Immunity</i> , 2022 ,	32.3	5
8	PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity.. <i>Nature Immunology</i> , 2022 ,	19.1	4
7	Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs. <i>Cancer Science</i> , 2016 , 107, 189-202	6.9	3
6	PD-1 preferentially inhibits the activation of low-affinity T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	1
5	T-cell-intrinsic and -extrinsic regulation of PD-1 function. <i>International Immunology</i> , 2021 , 33, 693-698	4.9	0
4	The regulation of PD-1/PD-L1 pathway and autoimmune diseases 2001 , 211-214		
3	The PD-1 and IL-10 pathways play a down-modulatory role in LP-BM5 retrovirus-induced murine immunodeficiency syndrome. <i>FASEB Journal</i> , 2008 , 22, 856.18	0.9	
2	PD-1 Research: History and Future Perspectives. <i>Trends in the Sciences</i> , 2019 , 24, 2_8-2_14	0	
1	Face of the Cover. <i>Trends in the Sciences</i> , 2019 , 24, 2_3-2_3	0	